Results 241 to 250 of about 103,862 (301)

An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance. [PDF]

Cancers (Basel)
Irving E, Morcavallo A, Vohhodina-Tretjakova J, Wijnhoven PWG, Beckett AL, Jacques MP, Evans RS, Moss JI, Staniszewska AD, Forment JV.   +9 more
europepmc   +1 more source

The Homeobox Genes: Classification, Regulation, Biological Functions, and Diseases

MedComm, Volume 7, Issue 4, April 2026.
Overview of the homeobox gene superfamily and its pathophysiological roles. The homeobox superfamily comprises several major classes, including ANTP, PRD, TALE, LIM, POU, and others. Among these, the HOX clusters (A–D) play critical roles in embryonic development specifically in conferring cellular identity, regulating morphogenesis, and guiding axial ...
Maedeh Dadzadi, Shahin Ramazi, Mona Darvazi, Sepideh Yoosefi, Melika Abbasi, Shirin Farsad   +5 more
wiley   +1 more source

Hematological toxicity of parp inhibitors in solid tumors: a systematic review and safety meta-analysis. [PDF]

Cancer Metastasis Rev
Maiorano BA, Catalano M, Maiorano MFP, Signori A, Loizzi V, Cormio G, Reni M, Roviello G, Necchi A.   +8 more
europepmc   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang, Yiqun Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Yun Liu, Zhen Hu   +9 more
wiley   +1 more source

Global Proteomic Determination of the Poly-Pharmacological Effects of PARP Inhibitors Following Treatment of High-Grade Serous Ovarian Cancer Cells. [PDF]

Int J Mol Sci
Perez JM, Barrera-Estrada V, Twigg CAI, Thomas SN.   +3 more
europepmc   +1 more source

Sulforaphane Synergizes With PD‐1 Blockade Through Activating CD8+ T Cells in Non–Small Cell Lung Cancer: Preclinical and Clinical Investigations

MedComm, Volume 7, Issue 4, April 2026.
SFN sensitizes PD‐1 blockade therapy in preclinical and clinical investigations, with no side effects. SFN elevates the antitumor response in peripheral and tumor microenvironment. ABSTRACT Anti‐PD‐1/PD‐L1 therapy has achieved promising success across several tumor types; however, its efficacy is still far from satisfactory in non–small cell lung ...
Jieyao Li, Jinyan Liu, Zheng Wang, Ming Zhao, Mingming You, Ziyi Fu, Caijuan Guo, Tengyue Zhang, Shasha Liu, Dongli Yue, Shuangning Yang, Yixin Li, Qun Gao, Yanfen Liu, Jianmin Huang, Liping Wang, Yi Zhang   +16 more
wiley   +1 more source

Has the Introduction of PARP Inhibitors Alleviated the Global, Regional and National Burden of Ovarian Cancer? A Segmented Regression Analysis of the Global Burden of Disease Study, 2007-2021. [PDF]

Int J Womens Health
Yang H.
europepmc   +1 more source

Progesterone Enhances the Sensitivity of Ovarian Cancer Cells to Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Suggesting a Role for Transcription-Replication Conflict-Related Pathways: An In Vitro Study. [PDF]

Cureus
Suizu E, Koyanagi T, Saga Y, Takahashi Y, Tamura K, Taneichi A, Takei Y, Mizukami H, Fujiwara H.   +8 more
europepmc   +1 more source

Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy. [PDF]

Int J Mol Sci
De K, Jana M, Chowdhury B, Calaf GM, Roy D.   +4 more
europepmc   +1 more source